openPR Logo
Press release

Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape report 2015 - 2030"

05-23-2019 12:20 PM CET | Health & Medicine

Press release from: Thelansis Knowledge Partners

Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape report 2015 - 2030"

Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape report 2015 - 2030"

Report Snapshot:

 Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract. Although it can involve any area of the GI tract, it most commonly affects the small intestine and/or colon. Crohn’s disease and ulcerative colitis are the two main diseases among a group of illnesses called inflammatory bowel disease (IBD). The symptoms of these two diseases are very similar, so it is sometimes difficult to establish a definitive diagnosis. One difference, however, is that ulcerative colitis affects only the colon, while Crohn’s disease may affect any part of the GI tract and often affects the end of the small bowel (the ileum) and the beginning of the colon.

 Thelansis "Crohn’s disease (CD) – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape. Half of all CD cases involve the ileum and colon and in 25% of cases, only the colon is affected. Approximately 15% of colitis cases are called indeterminate colitis because they cannot be classified as either ulcerative colitis or Crohn’s disease.

Market landscape:
 According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$5,425 MN in 2015 and expected to reach at ~$ 12,346 MN by the end of 2030 (15 years of markets projections; four years of historical data, current and eleven years of future market projections). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
A population-based study the total number of new cases of Crohn’s disease diagnosed each year (incidence) was 10.7 per 100,000 people or approximately 34,976 new cases per year, however, the number of new cases of ulcerative colitis diagnosed each year was ~41,250 new cases per year

Epidemiology and patient segmentation:
 According to Thelansis, globally ~ 2.3 MN patients are being diagnosed with Crohn’s disease (CD) in 2015 among which 8MM countries are comprised of ~75% of the total yearly reported cases. The total current market of Crohn’s disease is $ 3,821 MN in 2015 and expected to reach at ~$ 12,049 MN by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease

Crohn’s disease - biomarker level patient segmentation:
 Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)

Current therapy:
 One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.

There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA)
• Corticosteroids
• Antibiotics
• Immune modifiers
• Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.)
• Others

As many as 75% of Crohn’s disease patients required at least one surgical procedure during their lives, most often due to lack of response to medical therapy. Additional indications for surgery include intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. The overall goal of surgery in Crohn’s disease is to conserve bowel function and return the individual to the best possible quality of life. Continued use of medications is necessary to minimize the risk of recurrences.

Emerging therapies:
 As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS

The annual cost of therapy:
 According to the published literature review, Crohn’s disease is one of the most prevalent diseases in the United States including other developed and developing nations. For patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization cost.
 Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively

KOL’s Perspective:
 Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with moderate to severe stage of Crohn’s disease currently on biologics or any other form of targeted therapy
 More than 55% of the disease population diagnosed in their later stage of the disease, so the awareness around diagnosis procedure and technology need to be spread around to maximize the early diagnosis
 Multiple targets need to be identified and targeted to get control on the quality of life of the patients

Payer’s perspective:
From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce Crohn’s disease-related expenditures. The treatment of Crohn’s disease has changed dramatically since the launch of biosimilars of many TNF alpha biologics. Screening has and will continue to increase cure rates. Molecular profiling, coupled with biosimilars version of targeted therapies and the expanding role of immunotherapy, is becoming so effective and justifiably that the cost saving has been going up at each passing day.

The European nations regulatory bodies and payers are having a very positive mindset with respect to the approval and access of biosimilars, which will bring the country level disease burden as well as the treatment cost in coming years. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients.

As the name depicts Thelansis is specialized in “Therapy Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at, clientsupport@thelansis.com

Sales office:
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552

Delivery Office:
B-1030,
C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India +91-9899921259

sales@thelansis.com,
clientsupport@thelansis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thelansis "Crohn’s disease (CD) – Market Outlook and Competitive Landscape report 2015 - 2030" here

News-ID: 1750240 • Views:

More Releases from Thelansis Knowledge Partners

Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Autoimmune Hepatitis (AIH) – Market outlook, Epidemiology, Market Forecast and …
Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory, autoimmune disease in which one’s own immune system attacks healthy, normal liver cells. Etiology- The exact cause of autoimmune hepatitis is unknown. It is believed to be due to a combination of environmental, genetic, and immunologic factors. Classification- There are two clinically relevant types of AIH, including type 1and type 2. Type 1- also referred to as the classic type, is typically diagnosed in adulthood Type 2
Charcot–Marie–Tooth_Market Outlook and Competitive Landscape Report 2018 – 2030
Charcot–Marie–Tooth_Market Outlook and Competitive Landscape Report 2018 – …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Charcot–Marie–Tooth (CMT) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current clinical practice,
Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape 2015 - 2030
Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit

All 5 Releases


More Releases for Crohn’s

Crohn’s Disease Therapeutics Market Growth, Size, Share and Forecast 2019-2025
Improvement in the treatment modalities for Crohn’s disease has been observed in the developed economies such as the US and UK. The increased understanding of the disease followed with immunopathology is aiding the development of new targeted treatment solutions for Crohn’s disease, which includes the use of stem cell treatment, as they have a capability of modulating the immune system. The use of stem cell transplants for the treatment of
Crohn’s Disease Market Comprehensive Analysis & Global Forecast to 2022
Global Crohn’s Disease Market has been evaluated as growing market and expected that the market will reach high growth figures in the coming future. Crohn's disease is a type of inflammatory bowel disease (IBD), caused by a combination of environmental, immune and bacterial factors in genetically prone individuals. There are no medications, drugs or surgical procedures that can cure or prevent Crohn's disease. It is expected that the disease affects
Crohn’s Disease Market Booming Trend, Comprehensive Analysis & Global Foresigh …
Market Research Future has a Cooked Research report on Global Crohn’s Disease Market. Global Crohn’s Disease Market is growing rapidly and expected to continue its growth by the end of 2022 Crohn’s Disease Market Analysis by Procedures (Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging), By Key Companies, by Drugs - Forecast to 2022 Global Crohn’s Disease Market has been evaluated as growing
Crohn’s Disease Market Headed for Growth and Global Expansion by 2021
Crohn’s disease refers to long term inflammatory bowel disease, which causes inflammation of the lining of the digestive tract. It affects the large and small intestine and is generally diagnosed in persons within the age group of 20-29. It can have severe or acute outcomes. Signs and symptoms of Crohn’s disease develop slowly and gradually. Some of the common symptoms of this disease include abdominal pain and cramping, fever, fatigue,
Crohn’s Disease Drug Market and Pipeline Analysis
Under the umbrella of inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn’s disease in most cases affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from
Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides an overview of the Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape. Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the